SEC Company Response from CERAGENIX PHARMACEUTICALS, INC. (CIK 0001180743) — Aug 9, 2005

CERAGENIX PHARMACEUTICALS, INC. (CIK 0001180743)
Date: Aug. 9, 2005 · CIK: 0001180743 · Accession: 0001011034-05-000157

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-125967

Date

August 9, 2005

Author

/s/ Steven S.

Form

CORRESP

Company

CERAGENIX PHARMACEUTICALS, INC. (CIK 0001180743)

Letter

VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Re: Ceragenix Pharmaceuticals, f/k/a OnSource Corporation Registration Statement on Form SB-2 File No. 333-125967

Dear Mr. Lee:

On behalf of Ceragenix Pharmaceuticals, Inc., f/k/a OnSource Corporation (the "Company"), please accept this letter as notice that the Company requests that its request for acceleration of effectiveness of its Registration Statement on Form SB-2, SEC File No. 333-125967, as filed with the Commission on July 13, 2005, be withdrawn.

Thank you very much for your consideration.

Sincerely,
/s/ Steven S.
Porter

Show Raw Text

CORRESP
1
filename1.htm

CERAGENIX PHARMACEUTICALS, INC.

1444 Wazee Street, Suite 210

Denver, Colorado 80202

Telephone (720) 946-6440

Facsimile (303) 534-1860

August 9, 2005

VIA EDGAR AND FACSIMILE

Mr. Albert Lee, Staff Attorney

United States Securities and Exchange Commission

450 Fifth Street, N.W., Mail Stop 6010

Washington, DC  20549

Re:

Ceragenix Pharmaceuticals, f/k/a OnSource Corporation

Registration Statement on Form SB-2

File No. 333-125967

Dear Mr. Lee:

         On behalf of Ceragenix Pharmaceuticals, Inc., f/k/a OnSource Corporation (the "Company"), please accept this letter as notice that the Company requests that its request for acceleration of effectiveness of its Registration Statement on Form SB-2, SEC File No. 333-125967, as filed with the Commission on July 13, 2005, be withdrawn.

         Thank you very much for your consideration.

Sincerely,

/s/ Steven S.
  Porter

Steven S. Porter

Chief Executive Officer

SecProbe.io